New Therapy Reduces Mortality In Patients With Severe COPD
Patients with severe COPD may benefit more from therapy that combines salmeterol and fluticasone [SFC] than treatment with tiotropium, according to results from a long-term, multi-center study, “Investigating New Standards for Prophylaxis in Reducing Exacerbations” (INSPIRE) that directly compared the two therapies. [click link for full article]
More: continued here
Filed under: Clinical Trials on December 30th, 2007